These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7488278)

  • 1. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.
    Moreland LW; Pratt PW; Mayes MD; Postlethwaite A; Weisman MH; Schnitzer T; Lightfoot R; Calabrese L; Zelinger DJ; Woody JN
    Arthritis Rheum; 1995 Nov; 38(11):1581-8. PubMed ID: 7488278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.
    Moreland LW; Pratt PW; Sanders ME; Koopman WJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S153-9. PubMed ID: 8100752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.
    Moreland LW; Bucy RP; Tilden A; Pratt PW; LoBuglio AF; Khazaeli M; Everson MP; Daddona P; Ghrayeb J; Kilgarriff C
    Arthritis Rheum; 1993 Mar; 36(3):307-18. PubMed ID: 8095785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.
    van der Lubbe PA; Reiter C; Breedveld FC; Krüger K; Schattenkirchner M; Sanders ME; Riethmüller G
    Arthritis Rheum; 1993 Oct; 36(10):1375-9. PubMed ID: 8216397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action.
    van der Lubbe PA; Reiter C; Miltenburg AM; Krüger K; de Ruyter AN; Rieber EP; Bijl JA; Riethmüller G; Breedveld FC
    Scand J Immunol; 1994 Mar; 39(3):286-94. PubMed ID: 8128188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
    van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC
    Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts.
    Moreland LW; Pratt PW; Bucy RP; Jackson BS; Feldman JW; Koopman WJ
    Arthritis Rheum; 1994 Jun; 37(6):834-8. PubMed ID: 7911664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody.
    Choy EH; Chikanza IC; Kingsley GH; Corrigall V; Panayi GS
    Scand J Immunol; 1992 Aug; 36(2):291-8. PubMed ID: 1354392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.
    Tak PP; van der Lubbe PA; Cauli A; Daha MR; Smeets TJ; Kluin PM; Meinders AE; Yanni G; Panayi GS; Breedveld FC
    Arthritis Rheum; 1995 Oct; 38(10):1457-65. PubMed ID: 7575695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
    van Oosten BW; Lai M; Hodgkinson S; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Rudge P; McDougall A; McLeod JG; Adèr HJ; Polman CH
    Neurology; 1997 Aug; 49(2):351-7. PubMed ID: 9270561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.
    Jonker M; Slingerland W; Treacy G; van Eerd P; Pak KY; Wilson E; Tam S; Bakker K; Lobuglio AF; Rieber P
    Clin Exp Immunol; 1993 Sep; 93(3):301-7. PubMed ID: 8103714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric monoclonal CD4 antibody--a novel immunosuppressant for clinical heart transplantation.
    Meiser BM; Reiter C; Reichenspurner H; Uberfuhr P; Kreuzer E; Rieber EP; Riethmüller G; Reichart B
    Transplantation; 1994 Aug; 58(4):419-23. PubMed ID: 7915442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412.
    Llewellyn-Smith N; Lai M; Miller DH; Rudge P; Thompson AJ; Cuzner ML
    Neurology; 1997 Apr; 48(4):810-6. PubMed ID: 9109860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
    Choy EH; Pitzalis C; Cauli A; Bijl JA; Schantz A; Woody J; Kingsley GH; Panayi GS
    Arthritis Rheum; 1996 Jan; 39(1):52-6. PubMed ID: 8546738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
    Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM
    Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.